Disseminated intravascular coagulation (DIC) was recently observed intraoperatively in a patient who required removal of her right humeral head for pain relief. Despite normal preoperative coagulation parameters, the patient developed wound oozing soon after suturing the skin. Coagulation profile revealed decreased platelets, plasma coagulation factors and fibrinogen in association with elevated fibrin degradation products. To manage the DIC, urinastatin and gabexate mesilate, along with blood component replacement, proved effective.
There are some reports of coagulopathies associated with major spinal surgery 1,2 and orthopaedic surgery for metastatic carcinoma 3, 4 , however, to my knowledge, this is the first report of disseminated intravascular coagulation (DIC) associated with partial excision of the humeral head. Coagulation disorders occurring during orthopaedic surgery may be more common than previously thought.
CASE HISTORY
A 77-year-old woman weighing 45 kg was hospitalized for fracture of the surgical neck of the right humerus. Her medical history included diabetes mellitus and hypertension. The latter was being treated with a calcium antagonist. Diabetes mellitus was well controlled by subcutaneous injection of neutral insulin. Laboratory values showed that prothrombin time (PT) 12.7s (normal range 12 to 15s), activated partial thromboplastin time (APTT) 30.4 s (30 to 40 s), fibrinogen 215 mg/dl (200 to 400 mg/dl) and antithrombin (AT) III 80% (70 to 120%) were within the normal range. Internationalized Normalized Ratio (INR) is not available in our hospital. C reactive protein was 0.3 mg/dl (normal range <0.3 mg/dl) and white blood cell count was 4.4x 10 9 /l. Haemoglobin (Hb) was 8.9 g/dl. Her platelet count was 110x10 9 /l, bleeding time 3 minutes (normal <5 minutes) and fibrin degradation products (FDP) <5 µg/ml (normal <5 µg/ml). Pentazocine was used for pain relief instead of non-steroidal anti-inflammatory drugs. The patient was not treated with low dose heparin for deep vein thrombosis prophylaxis.
Two weeks after the injury the patient was scheduled for partial surgical removal of the humeral head. Anaesthesia was induced using 50 to 100 mg thiamylal, 50 µg fentanyl and 6 mg vecuronium bromide, and was maintained with sevoflurane, nitrous oxide and fentanyl. During anaesthesia, arterial blood pressure ranged from 90/45 to 170/90 mmHg and pulse rate from 55 to 110 beats/min. Blood loss was minimal and lactated Ringer's solution 1200 ml was infused intravenously. The operation took 80 minutes. The intraoperative course was uneventful. However, the patient developed oozing from the wound soon after suturing the skin. Repeat coagulation profile revealed a decreased platelet count (53x10 9 /l), Hb (6.8 g/dl), fibrinogen (147 mg/dl) and AT-III (32%) levels. Prolonged PT (15.8 s) and APTT (46.0 s) in association with elevated FDP (40 µg/ml) were seen. Two units (260 ml) of concentrated red cells and six units (480 ml) of fresh frozen plasma were transfused immediately and platelet concentrates were ordered. Urinastatin (200,000 units) and AT-III (500 mg) were infused. Gabexate mesilate was started in a continuous infusion (60 mg/h) and continued for 48 hours.
The patient was extubated and observed closely in the operating theatre. She continued to respond appropriately and remained normal in all respects except for minor blood loss from her wound. Soon after, 25 units (equivalent to 13 units in Australia) of irradiated platelets and additional fresh frozen plasma (4 units, 320 ml) were transfused in the recovery room and bleeding stopped completely. At that time, PT was 12.6 s and APTT was 31.0 s. The total blood loss was estimated as more than 900 ml. She remained alert, her condition stable and PT (13.4s), APTT (34.5s) and FDP (<5 µg/ml) at the time of discharge from recovery 18 hours postoperatively were all normal.
DISCUSSION
It has been reported that microangiopathic haemolytic anaemia occasionally occurs in patients with severe diabetic microangiopathy. Aoki Y et al reported a case of insulin-dependent diabetes mellitus complicated by microangiopathic haemolytic anaemia and chronic DIC. The patient showed fragmentation haemolytic anaemia and progressive diabetic microangiopathy, together with a mild elevation of serum fibrin degradation products 5 . In the present case, low haemoglobin and platelet count on admission were considered to be due to bleeding after the fracture.
DIC is a known complication of malignancy but is reported infrequently as a complication of bone removal. Its occurrence in this patient may have been triggered by the release of coagulant proteins after injury secondary to decortication or chipping of bone. Hypoxic acidotic tissues with stagnant blood flow probably release tissue thromboplastin either directly or through liberation of unknown toxins 6 . This case was characterized clinically by profuse uncontrollable haemorrhage from the surgical wound. Laboratory abnormalities indicated a consumptive coagulopathy. Acute disturbances of blood coagulation during surgery require rapid specific action in order to avoid a life-threatening situation.
The treatment of DIC is extremely complex, stemming from the fact that it complicates many different disorders and may have a variety of clinical manifestations. In addition, there is a lack of well-controlled studies regarding various methods of management in relatively homogeneous groups of patients. Therefore treatment continues to be controversial, and probably will remain so in the near future.
The removal of the original pathogenic factor is important as the first step of treatment. At the same time, anticoagulant treatment has been suggested as a primary therapy. Heparin, low molecular weight heparin, heparinoid and AT-III have been used in clinical practice. However, their benefits and efficacy have not been established. Synthetic protease inhibitors, which can block serine proteases, such as thrombin and plasmin, in the coagulative-fibrinolytic system, could prevent activation of coagulation factors and development of DIC if administered properly. They are approved for clinical use in Japan and used for DIC. Gabexate mesilate and urinastatin do not have the same spectrum of action but do have some common characteristics. It is possible that these inhibitors may prove superior to heparin and do not require AT-III for their activity, because both are competitive inhibitors of coagulative enzymes. The half-life of these agents in circulating human blood is only several minutes and shorter than that of heparin 7 . Yoshikawa T et al have shown a protective effect of gabexate mesilate 8 and urinastatin 9 against experimental DIC in rats.
In this case urinastatin, AT-III and gabexate mesilate were all used instead of heparin and seemed to be effective. No sign of thrombosis was seen and DIC did not lead to multiple organ failure.
In conclusion, to manage a case of acute DIC associated with removal of the humeral head, urinastatin and gabexate mesilate were effectively combined with blood component replacement. Their role remains unclear, as it is not possible to determine their contribution to the good clinical outcome. It remains possible that the completion of surgery, combined with blood component replacement alone, was enough to control bleeding and resolved the coagulation abnormalities.
